HZNP - Horizon drug dazodalibepy to treat Sjögren's syndrome meets primary endpoint in phase 2 trial

• Horizon Therapeutics ( NASDAQ: HZNP ) said on Monday its Phase 2 trial testing its drug, dazodalibep, to treat Sjögren’s syndrome met the primary endpoint in patients with moderate-to-high systemic disease.
• The company said at week 24, patients treated with dazodalibep achieved a 6.3-point reduction in their Sjögren's Syndrome Disease Activity Index (ESSDAI) score and patients treated with placebo achieved a 4.1-point reduction.
• The most common adverse events were COVID-19 infection, diarrhea, dizziness, ligament sprain and upper respiratory infections.

For further details see: